LigoCyte acquisition gives Takeda norovirus vaccine lead
This article was originally published in Scrip
Executive Summary
Takeda has entered into a definitive agreement to pay $60 million up front to acquire LigoCyte Pharmaceuticals, a privately held US vaccines company with a clinical-stage product for norovirus.